科室团队详细页面

[外文期刊] Clinical Investigation and Biological Mechanism of Tigecycline on Coagulation Disorders in Cancer Patients SCI

作者： Dawei Wang^1,2;Guoyan Wu^1,3;Xueping Li^1,4;Dejun Deng^1,5;Xiaopeng Tian^1,6;Jianming Zhang PhD^1,2;Yang Liang MD⁴;Yujun Dai MD PhD^1,4 （1 Asterisk with author names denotes non-ASH members.; 2 National Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; 3 Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 4 Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; 5 Shenzhen Luohu District Traditional Chinese Medical Hospital, Shenzhen, China; 6 Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China）

出处： Blood 2020 Vol.136 Suppl 1 P25

摘要： Tigecycline, a first representative of the new class of glycylcycline antibacterial drugs, has been approved by FDA for using in the treatment of comp ...

[外文期刊] Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis. SCIE SCI

作者： Jia H;Li Q;Yuan J;Sun X;Wu Z （Affiliations 1 Clinical Research Center, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, People\'s Republic of China. 2 Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, People\'s Republic of China. 3 Department of Oncology, Shanghai Medical College, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University, Shanghai, People\'s Republic of China. 4 Clinical Statistic Center, Fudan University Shanghai Cancer Center, Shanghai, People\'s Republic of China. 5 Department of Biostatistics, School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University, Shanghai, People\'s Republic of China.）

出处： The oncologist 2020 Vol.25 No.4 Pe644-e650

关键词： Colorectal cancer;Competing-risk model;Nomogram;SEER;Second primary malignancy

摘要： Purpose: This study aimed to profile the characteristics of patients with colorectal cancer (CRC) with a second primary malignancy (SPM) and to identi ...

[外文期刊] Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer(Article) SCIE SCI

作者： Zhao, Senlin^a^,b;Mi, Yushuai^c;Guan, Bingjie^d;Zheng, Binbin^d;Wei, Ping^b^,e^,f;Gu, Yanzi^g;Zhang, Zhengxiang^h;Cai, Sanjun^a^,b;Xu, Ye^a^,b;Li, Xinxiang^a^,b;He, Xuefeng^a^,b;Zhong, Xinyang^a^,b;Li, Guichao^b^,i;Chen, Zhiyu^b^,j;Li, Dawei^a^,b （a Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai, 200032, China; b Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong’an Road, Shanghai, 200032, China; c Department of Gastrointestinal Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, No. 247 Beiyuan Street, Jinan, 250033, China; d Department of General Surgery, Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, 85 Wujin Road, Shanghai, 200080, China; e Cancer Institute, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai, 200032, China; f Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai, 200032, China; g Department of Biobank, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai, 200032, China; h Department of Oncology, Yijishan Hospital of Wannan Medical College, No. 2 Zheshan Road, Wuhu, Anhui 241001, China; i Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai, 200032, China; j Department of Medical Oncology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai, 200032, China）

出处： Journal of Hematology and Oncology 2020 Vol.13 No.1 P156

关键词： Colorectal cancer liver metastasis;Exosome;M2 macrophage polarization;miR-934;Premetastatic niche

摘要： Background: Mounting evidence has demonstrated the vital importance of tumor-associated macrophages (TAMs) and exosomes in the formation of the premet ...

[外文期刊] Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer SCI

作者： N. Li^a;H. Bu^b;J. Liu^c;J. Zhu^d;Q. Zhou^e;L. Wang^f;R. Yin^g;X. Wu^h;S. Yaoⁱ;K. Gu^j;H. Zhang^k;G. Li^l;H. Pan^m;Q. Wuⁿ;R. An^o;X. Yang^p;Y. Zhu^q;X. Wan^r;L.Y. Wu^a （p Jiangxi Cancer Hospital, Nanchang, China r Shanghai First Maternity and Infant Hospital, Shanghai, China l Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China n Jiangsu Cancer Hospital, Nanjing, China c Sun Yat-sen University Cancer Center, Guangzhou, China e Chongqing University Cancer Hospital, Chongqing Cancer Institute and Chongqing Cancer Hospital, Chongqing, China u Jiangsu Hengrui Medicine Co. Ltd., Shanghai, China a National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China h Fudan University Shanghai Cancer Center, Shanghai, China s Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China j The First Affiliated Hospital of Anhui Medical University, Hefei, China d Zhejiang Cancer Hospital, Zhejiang, China o The First Affiliated Hospital of Xi\'an Jiaotong University, Xian, China f Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China q Shanghai General Hospital, Shanghai, China k The Fourth Hospital of Hebei Medical University, Shijiazhuang, China t Nanchang University First Affiliated Hospital, Nanchang, China b Qilu Hospital, Shandong University, Jinan, China m Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Zhejiang, China g West China Second University Hospital, Sichuan, China i The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China）

出处： Gynecologic Oncology 2020 Vol.159 Suppl 1 P159

[外文期刊] Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China SCIE SCI

作者： Ruihua Xu;Wei Wang;Bo Zhu;Xiaoyan Lin;Dong Ma;Lingjun Zhu;Qingchuan Zhao;Yongzhan Nie;Xiaohong Cai;Qi Li;Weijia Fang;Hongyan Li;Ning Wang;Yun Chen;Cike Peng;Honghao Fang;Lin Shen （Affiliations 1 Sun Yat-sen University Cancer Center, No. 651 Dongfeng East Road, Yuexiu District, Guangzhou, 510060, China. 2 The First People\'s Hospital of Foshan, No. 81 North Lingnan Road, Chancheng District, Foshan, 528000, China. 3 Xinqiao Hospital, Third Military Medical University, No. 83 Xinqiaozheng Street, Shapingbei District, Chongqing, 400037, China. 4 Fujian Medical University Union Hospital, No. 29 Xinquan Road, Gulou District, Fuzhou, 350001, China. 5 Guangdong General Hospital, No.106 Zhongshan Road, Yuexiu District, Guangzhou, 510245, China. 6 Jiangsu Province Hospital, No.300 Guangzhou Road, Gulou District, Nanjing, 210029, China. 7 Xijing Hospital, Fourth Military Medical University, No.15 West Road, Xincheng District, 710032, Xi\'an, Changle, China. 8 Sichuan Cancer Hospital and Institute, No.55 Sectional 4, South Renmin Road, Wuhou District, Chengdu, 610015, China. 9 Shanghai General Hospital, No.100 Haining Road, Hongkou District, Shanghai, 200080, China. 10 The First Hospital of Zhejiang Province, No.79 Qingchun Road, Shangcheng District, Hangzhou, 310002, China. 11 Eli Lilly and Company China Affiliate, No. 288 Shi Men Yi Lu, Jing\'an District, Shanghai, 200041, China. 12 Eli Lilly and Company China Affiliate, No. 288 Shi Men Yi Lu, Jing\'an District, Shanghai, 200041, China. Peng_ci_ke@lilly.com. 13 IQVIA, No. 968 West Beijing Road, Jing\'an District, Shanghai, 200063, China. 14 Beijing Cancer Hospital, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China.）

出处： BMC Cancer 2020 Vol.20 No.1 P131

关键词： Treatment patterns;Colorectal cancer;Medical records;Real-world evidence;China

摘要： Background Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. ...

[外文期刊] Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China. SCIE SCI EI

作者： Xin,Li;Zhen,Guo;Bailing,Li;Xiaolin,Zhang;Rui,Tian;Wei,Wu;Zhongwei,Zhang;Yunfei,Lu;Nan,Chen;Sean P,Clifford;Jiapeng,Huang （Affiliations 1 From the Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. 2 Department of Extracorporeal Circulation, Shanghai Chest Hospital, Shanghai, China. 3 Department of Cardiovascular Surgery, Changhai Hospital of Shanghai, Shanghai, China. 4 Department of Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. 5 Department of Emergency and Critical Care, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. 6 Department of Intensive Care Unit, Fudan University Shanghai Cancer Center, Shanghai, China. 7 Department of Critical Care, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China. 8 Department of Traditional Chinese Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. 9 Department of CRRT Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. 10 Department of Anesthesiology & Perioperative Medicine, University of Louisville, Louisville, Kentucky. 11 Department of Cardiovascular & Thoracic Surgery, University of Louisville, Louisville, Kentucky.）

出处： ASAIO journal (American Society for Artificial Internal Organs : 1992) 2020 Vol.66 No.5 P475-481

关键词： coronavirus disease 2019;extracorporeal membrane oxygenation;China.

摘要： Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone. The role and outcome of extracorpo ...

[外文期刊] A prognostic stemness biomarker CCDC80 reveals acquired drug resistance and immune infiltration in colorectal cancer.

作者： Wang, Wei‐Da;Wu, Guo‐Yan;Bai, Kun‐Hao;Shu, Ling‐Ling;Chi, Pei‐Dong;He, Si‐Yuan;Huang, Xin;Zhang, Qian‐Yi;Li, Liang;Wang, Da‐Wei;Dai, Yu‐Jun （1 State Key Laboratory of Oncology in South China, Guangzhou, China 2 Department of Hematologic Oncology, Sun Yat‐sen University Cancer Center, Guangzhou, China 3 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 4 Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 5 Department of Endoscopy, Sun Yat‐sen University Cancer Center, Guangzhou, China 6 The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston Texas,, USA 7 National Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China）

出处： Clinical & Translational Medicine 2020 Vol.10 No.6 P1-6

[外文期刊] Abstract 3275: GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial

作者： Lin Shen, Jifang Gong, Yuqin Song, Dingwei Ye, Zhihao Lu, Siyang Wang, Peijian Peng, Jianhua Chen, Ou Jiang, Guojun Zhang, Yuxian Bai, Jianji Pan, Chunguang Ma, Li Chen, Yi Ba, Qi Li, Ping Lu, Lingli Zhang, Xianli Yin, Shanzhi Gu, Huilai Zhang, Hang Su, Yongsheng Jiang, Bangwei Cao, Weiqing Han, Yan Sun, Feng Zhang, Weiwei Ouyang, Haiying Dong, Jianming Guo, Yabing Guo, Chongyuan Xu, Junyuan Qi, Li Wang, Jun Lv, Xiang Wang, Chris Chen, Jing Li, Yong Zheng, Ge Jin, Yining Yang, Guodong Zhao, Fan Yang, Kehui Xu, Xiangying Liang, Zhaoyang Pan and Haijin Meng （1 Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China;; 1 Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China;; 2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China;; 3 Department of Urology, Fudan University Shanghai Cancer Center,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;; 1 Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China;; 4 The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, China;; 4 The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, China;; 5 Thoracic Medicine Department I,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China;; 6 The Second General Hospital of Neijiang City, Neijiang, China;; 7 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;; 8 Harbin Medical University Cancer Hospital, Haerbin, China;; 9 Fujian Provincial Cancer Hospital, Fuzhou, China;; 3 Department of Urology, Fudan University Shanghai Cancer Center,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;; 10 The Fifth Affiliated Hospital of Nanchang University, Nanchang, China;; 11 Tianjin Medical University Cancer Institute&Hospital, Tianjin, China;; 12 Shanghai General Hospital, Shanghai, China;; 13 The First Affiliated Hospital of Xinxiang Medical School, Xinxiang, China;; 14 Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China;; 15 Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China;; 15 Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China;; 16 Lymphoma Department,Tianjin Medical University Cancer Institute&Hospital, Tianjin, China;; 17 The Fifth Medical Center of PLA General Hospital, Beijing, China;; 18 Tongji Hospital;Tongji Medical College Huazhong University of Science&Technology, Wuhan, China;; 19 Beijing Friendship Hospital, Capital Medical University, Beijing, China;; 15 Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China;; 20 Department of Oncological Radiotherapy, Peking University Cancer Hospital & Institute, Beijing, China;; 21 The First Affiliated Hospital of Bengbu Medical School, Bengbu, China;; 22 Guizhou Cancer Hospital, Guiyang, China;; 23 Zhengjiang Provincial People's Hospital, People's hospital of Hangzhou Medical College, Hangzhou, China;; 24 Zhongshan Hospital, Fudan University, Shanghai, China;; 25 Nanfang Hospital,The First Affiliated Hospital of Southern Medical School, Guangzhou, China;; 25 Nanfang Hospital,The First Affiliated Hospital of Southern Medical School, Guangzhou, China;; 26 Institute of Hematology & Blood Diseases Hospital, Tianjin, China;; 27 Jiangsu Province Hospital, Nanjing, China;; 28 Beijing Youan Hospital, Capital Medical University, Beijing, China;; 12 Shanghai General Hospital, Shanghai, China;; 29 WuXi Biologics (Shanghai) Co., Ltd., Shanghai, China;; 29 WuXi Biologics (Shanghai) Co., Ltd., Shanghai, China;; 29 WuXi Biologics (Shanghai) Co., Ltd., Shanghai, China;; 30 GloriousMed Technology Co.,Ltd., Beijing, China;; 30 GloriousMed Technology Co.,Ltd., Beijing, China;; 30 GloriousMed Technology Co.,Ltd., Beijing, China;; 31 Guangzhou Gloria Biosciences Co., Ltd., Beijing, China.; 31 Guangzhou Gloria Biosciences Co., Ltd., Beijing, China.; 31 Guangzhou Gloria Biosciences Co., Ltd., Beijing, China.; 31 Guangzhou Gloria Biosciences Co., Ltd., Beijing, China.; 31 Guangzhou Gloria Biosciences Co., Ltd., Beijing, China.）

出处： Cancer Research 2020

摘要： Background: GLS-010 is a novel fully human anti-PD-1 mAb developed by the OMT transgenic rat platform. In Phase 1a study, GLS-010 exhibited good toler ...

[外文期刊] Clinical relevance of ARF/ARL family genes and oncogenic function of ARL4C in endometrial cancer

作者： Jiawen Zhang;Qinyi Zhang;Cong Sun;Yanjuan Huang;Jing Zhang;Qingying Wang （Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China Department of Obstetrics and Gynecology, First Hospital of Zibo, Shandong, China School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China Department of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, China;Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;Corresponding author at: Department of Integrated Therapy, Shanghai Cancer Center, Fudan University, Shanghai, China, Address: No.255, Dong’An Road, Shanghai, 200032, China. Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China;Corresponding author at: Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China, Address: No.301 Yanchang Middle Road, Shanghai, 200072, China.）

出处： Biomedicine & Pharmacotherapy 2020

关键词： ARF/ARL family;ARL4C;Endometrial cancer;Prognosis;Metformin

摘要： Members of ADP-ribosylation factor (ARF)/ARF-like protein (ARL) family regulate malignant phenotype of cancer cells. The present study aims to investi ...

[外文期刊] Intensity Modulated Radiation Therapy Plus Etoposide/Cisplatin for Patients With Limited Advanced Unresectable Thymic Epithelial Tumors: A Prospective Phase 2 Study

作者： Fan, Xing-Wen^{1, 2};Yang, Yu¹;Wang, Hong-Bing¹;Xu, Yin¹;Kang, Mei³;Xie, Li-Yi^{1, 2};Li, Ling^{1, 2};Fang, Wen-Tao⁴;Zhao, Kuai-Le^{1, 2};Chen, Hai-Quan^{2, 5};Xiang, Jia-Qing^{2, 5};Ung, Yee C.⁶;Wong, C. Shun⁶;Jiang, Guo-Liang^{1, 2, 7};Wu, Kai-Liang^{1, 2} （1 Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China (2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China (3 Clinical Research Center, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (4 Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, China (5 Department of Thoracic Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China (6 Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada (7 Department of Radiation Oncology, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai Proton and Heavy Ion Center, Shanghai, China）

出处： International Journal of Radiation Oncology Biology Physics 2020

摘要： Purpose: This prospective phase 2 study evaluated the efficacy and safety of intensity modulated radiation therapy plus etoposide/cisplatin (EP) for p ...